Oncogenic driver mutations in non-small cell lung cancer: Past, present and future

Table 1 Selected oncogenic drivers and their treatments in non-small cell lung cancer

	Targeted therapy	ORR	PFS	OS
EGFR	Erlotinib1[40]	62%-83%	9.7-13.1 mo	19.3-26.3 mo
	Gefitinib1[4]	73.7%	9.5 mo	22 mo
	Afatinib1[5]	56%-67%	11.1 mo	25.8 mo
	Dacomitinib1[127]	74.9%	14.7 mo	34 mo
	Osimertinib1[128]	80%	18.9 mo	38.6 mo
ALK	Crizotinib1[53]	75.5%	11 mo	57 mo
	Ceritinib1[129]	72.5%	16.6 mo	NA
	Brigatinib0[130]	79%	24 mo	NA
	Alectinib1[131]	82.9%	35 mo	NA
	Lorlatinib1[54]	76%	NA	NA
ROS1	Crizotinib1[132]	63-72%	15.9-19.2 mo	51 mo
	Lorlatinib1[133]	62%	19.3 mo	NA
	Entrectinib1[134]	77%	19 mo	NA
BRAF	Dabrafenib-trametinib1[135]	64%	10.9 mo	24.6 mo
MET	Crizotinib[50]	32%	7.3 mo	NA
	Cabozantinib[136]	NA	NA	NA
	Capmatinib1[137]	68%	9.7 mo	NA
	Tepotinib[138]	46%	NA	NA
NTRK	Entrectinib1[139]	70%	NA	NA
	Larotrectinib1[140]	75%	NA	NA
RET	Selpercatinib1[141]	85%	NA	NA
	Pralsetinib1[121]	70%	NA	NA
KRAS	Sotorasib[142]	32.2%	10.2 mo	NA
	Adagrasib[143]	45%	NA	NA
HER2	Trastuzumab-deruxtecan[144]	62%	14 mo	NA
NRG1	Afatinib[112]	NA	NA	NA

¹Food and Drug Administration approved. ORR: Objective response rate; PFS: Progression-free survival; OS: Overall survival; EGFR: Epidermal growth factor receptor; ALK: Anaplastic lymphoma kinase; ROS1: c-ROS oncogene 1; NTRK: Neurotrophic receptor tyrosine kinase; RET: Rearranged during transfection; KRAS: Kirsten rat sarcoma; HER2: Human epidermal growth factor 2; NRG1: Neuregulin-1; BRAF: V-raf murine sarcoma viral oncogene homolog B. NA: Not available.